Barclays Raises Price Target#
Barclays has increased its price target for Quest Diagnostics shares (NYSE:DGX) from $225 to $230, while maintaining an Overweight rating. Currently, the stock is trading at $205.04, showing a 23% increase over the past year and a 14% rise year-to-date.
Strong Business Momentum#
The firm highlighted a solid performance from Quest Diagnostics, which indicates strong momentum in its business operations. This resilience is particularly noteworthy given the challenging economic environment that many companies face. Barclays believes that the company's management may have provided conservative guidance, suggesting that future results could exceed expectations.
Impressive Financial Results#
In its recent financial report for the first quarter of 2026, Quest Diagnostics surpassed analysts' expectations. The company reported an adjusted earnings per share (EPS) of $2.50, exceeding the forecast of $2.37, marking a 13.1% increase from the same quarter last year. Additionally, Quest Diagnostics generated revenue of $2.9 billion, surpassing the anticipated $2.83 billion, which reflects a 9.2% growth year-over-year. These results indicate a strong start for the company in 2026, showcasing its solid financial health.
Looking Ahead#
As of now, Quest Diagnostics has not announced a date for its next earnings report, but the recent performance and Barclays' optimistic outlook suggest a positive trajectory for the company moving forward.